JP2018526405A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526405A5
JP2018526405A5 JP2018512525A JP2018512525A JP2018526405A5 JP 2018526405 A5 JP2018526405 A5 JP 2018526405A5 JP 2018512525 A JP2018512525 A JP 2018512525A JP 2018512525 A JP2018512525 A JP 2018512525A JP 2018526405 A5 JP2018526405 A5 JP 2018526405A5
Authority
JP
Japan
Prior art keywords
alkyl
group
groups
cycloalkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526405A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/070839 external-priority patent/WO2017042121A1/en
Publication of JP2018526405A publication Critical patent/JP2018526405A/ja
Publication of JP2018526405A5 publication Critical patent/JP2018526405A5/ja
Pending legal-status Critical Current

Links

JP2018512525A 2015-09-09 2016-09-05 [{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用 Pending JP2018526405A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15184449 2015-09-09
EP15184449.5 2015-09-09
EP16154638 2016-02-08
EP16154638.7 2016-02-08
PCT/EP2016/070839 WO2017042121A1 (en) 2015-09-09 2016-09-05 [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2018526405A JP2018526405A (ja) 2018-09-13
JP2018526405A5 true JP2018526405A5 (enExample) 2019-09-05

Family

ID=56855466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512525A Pending JP2018526405A (ja) 2015-09-09 2016-09-05 [{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用

Country Status (4)

Country Link
US (1) US20180354962A1 (enExample)
EP (1) EP3347358B1 (enExample)
JP (1) JP2018526405A (enExample)
WO (1) WO2017042121A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018095877A1 (en) * 2016-11-28 2018-05-31 Boehringer Ingelheim International Gmbh Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10253004B2 (en) * 2017-01-26 2019-04-09 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3580222B1 (en) * 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
WO2014019186A1 (en) * 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3036237A4 (en) * 2013-08-23 2017-01-25 Fujian Haixi Pharmaceuticals Co. Ltd Carboxylic acid compounds in treatment of diabetes mellitus

Similar Documents

Publication Publication Date Title
JP2020505393A5 (enExample)
JP2018526352A5 (enExample)
JP2020505400A5 (enExample)
JP2020505394A5 (enExample)
JP2019535792A5 (enExample)
JP2020505402A5 (enExample)
JP2020514315A5 (enExample)
JP2020506205A5 (enExample)
JP2019532110A5 (enExample)
JP2015511613A5 (enExample)
JP2016531868A5 (enExample)
JP2013507423A5 (enExample)
JP2017503760A5 (enExample)
JP2016530259A5 (enExample)
JP2015500843A5 (enExample)
JP2015516427A5 (enExample)
JP2016515560A5 (enExample)
WO2015021396A3 (en) Tricyclic benzoxaborole compounds and uses thereof
JP2016525075A5 (enExample)
JP2016506958A5 (enExample)
JP2016531858A5 (enExample)
JP2018504437A5 (enExample)
JP2017531677A5 (enExample)
JP2016508506A5 (enExample)
JP2020500916A5 (enExample)